A clinical briefing on Ovidrel availability in 2026 — shortage timeline, prescribing implications, alternative trigger protocols, and tools to help your patients.
Ovidrel (Choriogonadotropin Alfa, 250 mcg/0.5 mL prefilled syringe) remains the only commercially available recombinant hCG (r-hCG) trigger shot in the United States. While it is not currently listed on the FDA's Drug Shortage database, many reproductive endocrinology practices report intermittent difficulty obtaining it through standard pharmacy channels.
This briefing covers the current supply landscape, prescribing implications, alternative trigger protocols, cost and access considerations, and tools available to help your patients locate Ovidrel when availability is constrained.
The supply pressure on Ovidrel is not an isolated event — it's part of a broader disruption across the hCG medication class that has been building for several years:
The intermittent difficulty in obtaining Ovidrel has several practical implications for providers:
Consider discussing pharmacy logistics with patients at the start of their stimulation cycle — before the trigger shot is needed. Specifically:
When Ovidrel is unavailable, the following alternatives are well-established:
Regardless of which trigger is used, standard monitoring applies: serum estradiol levels and ultrasound assessment of follicular maturity should guide the trigger decision. The threshold for withholding hCG-based triggers due to OHSS risk (e.g., >20 follicles ≥10 mm, estradiol >3,000-4,000 pg/mL) remains an important clinical decision point.
Ovidrel distribution in the U.S. follows a specialty pharmacy model:
Ovidrel pricing creates an additional barrier for many patients:
For patients struggling with cost, a detailed breakdown of savings options is available at our patient-facing savings guide, which you can share directly.
Several resources can help streamline the process of locating Ovidrel for your patients:
Consider designating one staff member (typically a nurse coordinator or pharmacy liaison) to manage medication sourcing for your patients. A standardized workflow — check stock at time of protocol initiation, confirm availability before trigger day, have a documented alternative plan — can prevent last-minute scrambles.
There are no r-hCG biosimilars currently approved or in late-stage development for the U.S. market. Ovidrel's position as the sole recombinant hCG product is unlikely to change in the near term. This means that the supply dynamics described above will likely persist.
Proactive planning — including maintaining relationships with multiple specialty pharmacies, standardizing backup trigger protocols, and educating patients about the importance of early prescription fills — remains the most effective strategy for managing this ongoing challenge.
Ovidrel supply constraints are a practical reality in 2026 that affects patient care and practice workflow. While not a formal shortage, the combination of single-source manufacturing, specialty distribution, and class-wide hCG supply pressure creates access challenges that demand proactive management.
For more clinical resources on Ovidrel, including drug interactions and side effect profiles, see:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
